UC Davis Health launches new Invasive E. coli disease vaccine trial
2023年5月16日 · A new clinical trial by UC Davis Health researchers will evaluate the efficacy and safety of an experimental vaccine in preventing Invasive E. coli disease (IED). The vaccine, ExPEC9V, will be tested in adults aged 60 years and older with a history of urinary tract infections.
A randomized phase 1/2a trial of ExPEC10V vaccine in adults
2024年6月14日 · ExPEC10V is a 10-valent E. coli bioconjugate vaccine candidate for the prevention of IED caused by 10 O-serotypes most frequently associated with invasive E. coli infections 23,...
A vaccine for E. coli ? Meet a researcher hot on the trail
2019年4月24日 · A vaccine for E. coli? Meet a researcher hot on the trail A particular strain of the bacteria can be deadly for those over the age of 60—and it’s not the kind that causes food poisoning. But this Janssen researcher is committed to finding a preventive treatment.
Sanofi announces agreement for potential first-in-class vaccine …
2005年10月3日 · Sanofi announces today that it has entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, currently in Phase 3.
Broad protective vaccination against systemic Escherichia coli …
A vaccine against E. coli is essential to both prevent the spread to susceptible hosts and reduce death and disease. Using a comprehensive computational virulome and metagenomics approach, we identified a surface-exposed, pathogen-specific autotransporter protein, SinH, as a potential vaccine candidate for E. coli infection. The known virulence ...
Vaccines Against Escherichia coli - PubMed
Escherichia coli has a complex and versatile nature and continuously evolves from non-virulent isolates to highly pathogenic strains causing severe diseases and outbreaks. Broadly protective vaccines against pathogenic E. coli are not available and the rising in …
Janssen Enters into Agreement with Sanofi to Advance Potential …
2023年10月3日 · The lead vaccine candidate is currently being evaluated in the Phase 3 E.mbrace study for the prevention of invasive E. coli disease (IED) in adults aged 60 years and older. IED occurs when bacteria that normally reside in the intestines leave the intestinal tract and infect other parts of the body.
Sanofi partners J&J on E. coli vaccine - pharmaphorum
2 天之前 · The nine-valent ExPEC9V bioconjugate vaccine, targeting nine separate strains of E. coli and also known as VAC52416, is currently being compared to placebo in a phase 3 trial involving around...
Janssen Enters into Agreement with Sanofi to Advance Potential …
2023年10月3日 · The lead vaccine candidate is currently being evaluated in the Phase 3 E.mbrace study for the prevention of invasive E. coli disease (IED) in adults aged 60 years and older. IED occurs when bacteria that normally reside in the intestines leave the intestinal tract and infect other parts of the body.
Vaccines against extraintestinal pathogenic Escherichia coli …
Novel mucosal vaccine designs for other pathogens may shed light into how ExPEC vaccines can be improved. For example, the enterotoxigenic E. coli vaccine ETVAX utilizes inactivated whole-cell bacteria to overexpress colonization antigens on cell surfaces.